BACKGROUND: HIV-1 incidence calculation currently includes recency classification by HIV-1 incidence assay and unsuppressed viral load (VL ≥ 1000 copies/mL) in a recent infection testing algorithm (RITA). However, persons with recent classification not virally suppressed and taking antiretroviral (ARV) medication may be misclassified. SETTING: We used data from 13 African household surveys to describe the impact of an ARV-adjusted RITA on HIV-1 incidence estimates. METHODS: HIV-seropositive samples were tested for recency using the HIV-1 Limiting Antigen (LAg)-Avidity enzyme immunoassay, HIV-1 viral load, ARVs used in each country, and ARV drug resistance. LAg-recent result was defined as normalized optical density values ≤1.5. We compared HIV-1 incidence estimates using 2 RITA: RITA1: LAg-recent + VL ≥ 1000 copies/mL and RITA2: RITA1 + undetectable ARV. We explored RITA2 with self-reported ARV use and with clinical history. RESULTS: Overall, 357 adult HIV-positive participants were classified as having recent infection with RITA1. RITA2 reclassified 55 (15.4%) persons with detectable ARV as having long-term infection. Those with detectable ARV were significantly more likely to be aware of their HIV-positive status (84% vs. 10%) and had higher levels of drug resistance (74% vs. 26%) than those without detectable ARV. RITA2 incidence was lower than RITA1 incidence (range, 0%-30% decrease), resulting in decreased estimated new infections from 390,000 to 341,000 across the 13 countries. Incidence estimates were similar using detectable or self-reported ARV (R2 > 0.995). CONCLUSIONS: Including ARV in RITA2 improved the accuracy of HIV-1 incidence estimates by removing participants with likely long-term HIV infection.
BACKGROUND: HIV-1 incidence calculation currently includes recency classification by HIV-1 incidence assay and unsuppressed viral load (VL ≥ 1000 copies/mL) in a recent infection testing algorithm (RITA). However, persons with recent classification not virally suppressed and taking antiretroviral (ARV) medication may be misclassified. SETTING: We used data from 13 African household surveys to describe the impact of an ARV-adjusted RITA on HIV-1 incidence estimates. METHODS: HIV-seropositive samples were tested for recency using the HIV-1 Limiting Antigen (LAg)-Avidity enzyme immunoassay, HIV-1 viral load, ARVs used in each country, and ARV drug resistance. LAg-recent result was defined as normalized optical density values ≤1.5. We compared HIV-1 incidence estimates using 2 RITA: RITA1: LAg-recent + VL ≥ 1000 copies/mL and RITA2: RITA1 + undetectable ARV. We explored RITA2 with self-reported ARV use and with clinical history. RESULTS: Overall, 357 adult HIV-positive participants were classified as having recent infection with RITA1. RITA2 reclassified 55 (15.4%) persons with detectable ARV as having long-term infection. Those with detectable ARV were significantly more likely to be aware of their HIV-positive status (84% vs. 10%) and had higher levels of drug resistance (74% vs. 26%) than those without detectable ARV. RITA2 incidence was lower than RITA1 incidence (range, 0%-30% decrease), resulting in decreased estimated new infections from 390,000 to 341,000 across the 13 countries. Incidence estimates were similar using detectable or self-reported ARV (R2 > 0.995). CONCLUSIONS: Including ARV in RITA2 improved the accuracy of HIV-1 incidence estimates by removing participants with likely long-term HIV infection.
Authors: Oliver Laeyendecker; Ronald H Gray; M Kate Grabowski; Steven J Reynolds; Anthony Ndyanabo; Joseph Ssekasanvu; Reinaldo E Fernandez; Maria J Wawer; David Serwadda; Thomas C Quinn Journal: AIDS Res Hum Retroviruses Date: 2019-01-29 Impact factor: 2.205
Authors: Yen T Duong; Trudy Dobbs; Yvonne Mavengere; Julius Manjengwa; Erin Rottinghaus; Suzue Saito; Naomi Bock; Neena Philip; Jessica Justman; George Bicego; John N Nkengasong; Bharat S Parekh Journal: AIDS Res Hum Retroviruses Date: 2019-08-15 Impact factor: 2.205
Authors: Yen T Duong; Maofeng Qiu; Anindya K De; Keisha Jackson; Trudy Dobbs; Andrea A Kim; John N Nkengasong; Bharat S Parekh Journal: PLoS One Date: 2012-03-27 Impact factor: 3.240
Authors: Yen T Duong; Reshma Kassanjee; Alex Welte; Meade Morgan; Anindya De; Trudy Dobbs; Erin Rottinghaus; John Nkengasong; Marcel E Curlin; Chonticha Kittinunvorakoon; Boonyos Raengsakulrach; Michael Martin; Kachit Choopanya; Suphak Vanichseni; Yan Jiang; Maofeng Qiu; Haiying Yu; Yan Hao; Neha Shah; Linh-Vi Le; Andrea A Kim; Tuan Anh Nguyen; William Ampofo; Bharat S Parekh Journal: PLoS One Date: 2015-02-24 Impact factor: 3.240
Authors: Suzue Saito; Yen T Duong; Melissa Metz; Kiwon Lee; Hetal Patel; Katrina Sleeman; Julius Manjengwa; Francis M Ogollah; Webster Kasongo; Rick Mitchell; Owen Mugurungi; Frank Chimbwandira; Crispin Moyo; Vusumuzi Maliwa; Helecks Mtengo; Tepa Nkumbula; Clement B Ndongmo; Nora Skutayi Vere; Geoffrey Chipungu; Bharat S Parekh; Jessica Justman; Andrew C Voetsch Journal: J Int AIDS Soc Date: 2017-11 Impact factor: 5.396
Authors: Jeffrey W Eaton; Tim Brown; Robert Puckett; Robert Glaubius; Kennedy Mutai; Le Bao; Joshua A Salomon; John Stover; Mary Mahy; Timothy B Hallett Journal: AIDS Date: 2019-12-15 Impact factor: 4.177
Authors: Ethan Klock; Ethan Wilson; Reinaldo E Fernandez; Estelle Piwowar-Manning; Ayana Moore; Barry Kosloff; Justin Bwalya; Nomtha Bell-Mandla; Anelet James; Helen Ayles; Peter Bock; Deborah Donnell; Sarah Fidler; Richard Hayes; Susan H Eshleman; Oliver Laeyendecker Journal: J Int AIDS Soc Date: 2021-12 Impact factor: 6.707
Authors: Shelley N Facente; Eduard Grebe; Andrew D Maher; Douglas Fox; Susan Scheer; Mary Mahy; Shona Dalal; David Lowrance; Kimberly Marsh Journal: JMIR Public Health Surveill Date: 2022-03-11